{"nctId":"NCT04838613","briefTitle":"Study of Diagnostic Performance of [18F]CTT1057 in BCR","startDateStruct":{"date":"2021-09-30","type":"ACTUAL"},"conditions":["Prostatic Neoplasms","Prostate Cancer","Recurrence"],"count":190,"armGroups":[{"label":"PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versa","type":"EXPERIMENTAL","interventionNames":["Drug: [18F]CTT1057","Drug: [68Ga]Ga-PSMA-11"]}],"interventions":[{"name":"[18F]CTT1057","otherNames":[]},{"name":"[68Ga]Ga-PSMA-11","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Signed informed consent must be obtained prior to participation in the study\n* Biopsy proven prostate adenocarcinoma.\n* Biochemical recurrence following initial definitive therapy (with either RP or curative intent radiation therapy) as defined:\n\nby AUA criteria (Cookson et al 2007) for patients who have undergone RP: Initial serum PSA of ≥0.2 ng/ml measured at least 6 weeks after RP with a second confirmatory persistent PSA level of \\>0.2 ng/ml, or by ASTRO-Phoenix criteria (Roach et al 2006) for patients who have undergone curative-intent radiation therapy (RT): Rise of serum PSA measurement of 2 or more ng/mL above the nadir PSA observed post RT.\n\n* ECOG performance status 0-2\n* Participants must be adults ≥ 18 years of age\n\nExclusion Criteria:\n\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)\n* Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation, including, but not limited to, current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and COVID-19\n* Prior major surgery undergone less than 12 weeks prior to screening (with the exception of any surgery related to prostatic cancer)\n* Known allergy, hypersensitivity, or intolerance to \\[18F\\]CTT1057, \\[68Ga\\]Ga-PSMA-11, or to CT contrast\n* Prior and current use of PSMA targeted therapies\n* Prior ADT (first or second generation), including LHRH analogues (agonists or antagonists), within 9 months before screening\n* Any 5-alpha reductase inhibitors within 30 days before screening\n* Use of other investigational drugs within 30 days before screening\n* Castration-resistant patients\n* Patient with small cell or neuroendocrine PCa in more than 50% of biopsy tissue\n* Prior salvage surgery or salvage radiation therapy","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F)","description":"Region-level correct localization rate (CLR) is defined as the percentage of regions containing at least one True Positive (TP) lesion (exactly localized correspondence between PET imaging and the reference standard), regardless of any co-existent False Positive (FP) findings within the same region, out of all regions containing at least one PET-positive finding.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"73.3","spread":null},{"groupId":"OG002","value":"67.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Patient-level Positive Predictive Value (PPV) (With Anatomical Localization) of Vidoflufolastat (18F)","description":"Patient-level positive predictive value (PPV) is defined as the percentage of participants who have at least one True Positive (TP) lesion (exactly localized correspondence between PET imaging and the reference standard), regardless of any co-existent False Positive (FP) findings, out of all participants who are PET/CT scan positive.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"74.5","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Sensitivity of Vidoflufolastat (18F)","description":"Patient-level sensitivity is defined as the percentage of participants who test positive on vidoflufolastat (18F) and Composite Truth Standard (CTS) (True Positive (TP)) among those that are CTS positive (True Positive (TP) or False Negative (FN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"68.3","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Specificity of Vidoflufolastat (18F)","description":"Patient-level specificity is defined as the percentage of participants who test negative on vidoflufolastat (18F) and CTS (True Negative (TN)) among those that are CTS negative (True Negative (TN) or False Positive (FP)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"86.1","spread":null},{"groupId":"OG002","value":"80.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Negative Predictive Value (NPV) of Vidoflufolastat (18F)","description":"Patient-level negative predictive value is defined as the percentage of participants who are both vidoflufolastat (18F) and CTS negative (True Negative (TN)) among those who test negative on vidoflufolastat (18F) (True Negative (TN) or False Negative (FN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"82.1","spread":null},{"groupId":"OG002","value":"80.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Accuracy of Vidoflufolastat (18F)","description":"Patient-level accuracy is defined as the percentage of participants who are CTS and vidoflufolastat (18F) positive (True Positive (TP)) and negative (True Negative (TN)) among those participants that identified on vidoflufolastat (18F) (True Positive (TP), True Negative (TN), False Positive (FP) or False Negative (FN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"79.5","spread":null},{"groupId":"OG002","value":"75.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Correct Detection Rate (CDR)","description":"Patient-level correct detection rate (CDR) is defined as the percentage of participants who have at least one True Positive (TP) lesion (exactly localized correspondence between PET imaging and the reference standard), regardless of any co-existent False Positive (FP) findings, out of all participants who are scanned.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"25.5","spread":null},{"groupId":"OG002","value":"24.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Detection Rate","description":"Patient-level detection rate is defined as the percentage of participants who have at least one PET positive lesion, regardless of True Positive (TP) or False Positive (FP) findings, out of all participants who are scanned.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":null},{"groupId":"OG001","value":"34.2","spread":null},{"groupId":"OG002","value":"37.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level Sensitivity of Vidoflufolastat (18F) (Overall)","description":"Region level sensitivity is defined as the percentage of regions that test positive on both vidoflufolastat (18F) and CTS (True Positive (TP)) among those regions that are CTS positive (True Positive (TP) or False Negative (FN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null},{"groupId":"OG001","value":"54.3","spread":null},{"groupId":"OG002","value":"57.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Region Level Specificity of Vidoflufolastat (18F)","description":"Region level specificity is defined as the percentage of regions that test negative on both vidoflufolastat (18F) and CTS (True Negative (TN)) among those regions that are CTS negative (False Positive (FP) or True Negative (TN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"97.8","spread":null},{"groupId":"OG002","value":"97.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Region Level Negative Predictive Value (NPV) of Vidoflufolastat (18F)","description":"Region level negative predictive value is defined as the percentage of regions that are CTS and vidoflufolastat (18F) negative (True Negative (TN)) among those regions that test negative on vidoflufolastat (18F) (True Negative (TN) or False Negative (FN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"95.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Region Level Accuracy of Vidoflufolastat (18F)","description":"Region level accuracy is defined as the percentage of regions that are CTS andvidoflufolastat (18F) positive (True Positive (TP)) and negative (True Negative (TN)) among those regions that identified on vidoflufolastat (18F) (True Positive (TP), True Negative (TN), False Positive (FP) and False Negative (FN)).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"93.4","spread":null},{"groupId":"OG002","value":"93.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Positive Predictive Value (PPV) of Vidoflufolastat (18F) Related to PSA Levels","description":"Patient-level positive predictive value related to PSA levels is defined as the percentage of participants who have at least one True Positive (TP) lesion (exactly anatomically localized correspondence between vidoflufolastat (18F) PET imaging and the reference standard), regardless of any co-existent False Positive (FP) findings, out of all participants who are vidoflufolastat (18F) positive, stratified by PSA levels. This endpoint was analyzed in each of the following subgroups: PSA ≤ 0.5 ng/mL; 0.5 ng/mL\\<PSA≤1 ng/mL; 1 ng/mL\\<PSA≤2 ng/mL; 2 ng/mL\\<PSA≤5 ng/mL; PSA \\> 5 ng/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"61.5","spread":null},{"groupId":"OG002","value":"51.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"90.9","spread":null},{"groupId":"OG002","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"85.7","spread":null},{"groupId":"OG002","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Overview of Adverse Events (AEs) and Treatment Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a subject or clinical investigation subject.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Vidoflufolastat (18F) Scan Inter-reader Variability","description":"Inter-reader variability is defined as the agreement among three readers determination of vidoflufolastat (18F) images.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Vidoflufolastat (18F) Scan Intra-reader Variability","description":"Intra-reader variability is defined as the within-reader agreement for two different time points of vidoflufolastat (18F) images.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"61.2","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Concordance Between Vidoflufolastat (18F) and Gallium (68Ga) Gozetotide for Detection of Lesions at Lesion Level Using Central Reads (Overall)","description":"Concordance between vidoflufolastat (18F) and gallium (68Ga) gozetotide for detection of PSMA-positive lesions (location and number) using central reads.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"50.9","spread":null},{"groupId":"OG002","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Patient Management Plans Attributed to the Vidoflufolastat (18F) PET/CT Scan","description":"Change in patient management plans attributed to the PET/CT scan is defined as the percentage of participants who underwent a change in intended treatment plan attributed to the vidoflufolastat (18F) PET/CT scan as assessed by pre and post imaging questionnaires.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":171},"commonTop":["Asthenia","COVID-19","Lipase increased","Amylase increased","Blood creatine phosphokinase increased"]}}}